Eli Lilly widens lead in weight loss market after Novo Nordisk trial disappointment
Novo Nordisk shares fell sharply after trial data showed its new drug CagriSema underperformed Eli Lilly’s Zepbound. The results solidify Lilly’s market lead.
洞察:
Novo Nordisk A/S released late-stage trial results for CagriSema (drug/trial) on February 24, 2026, showing that the treatment produced less weight loss than Eli Lilly and Company's Zepbound (tirzepatide) over an 84-week period. The announcement prompted a sharp market reaction, with Novo shares falling 16% and Lilly shares rising 5%. This outcome is significant because it weakens the competitive position of Novo Nordisk A/S and reinforces the market and valuation advantage held by Eli Lilly and Company in the global diabetes and obesity drug market.
The trial results arrive as Eli Lilly and Company is consolidating its position in the obesity and diabetes sector, supported by an expected United States 
US approval timeline for its rival oral pill. The comparative data between CagriSema (drug/trial) and Zepbound (tirzepatide)—which is also marketed as Mounjaro (European name for tirzepatide)—highlights the shifting dynamics between the two pharmaceutical leaders. For Novo Nordisk A/S, the underperformance of the drug comes after prior CagriSema setbacks, posing a challenge to the market standing of its existing Wegovy (injection).
US approval timeline for its rival oral pill. The comparative data between CagriSema (drug/trial) and Zepbound (tirzepatide)—which is also marketed as Mounjaro (European name for tirzepatide)—highlights the shifting dynamics between the two pharmaceutical leaders. For Novo Nordisk A/S, the underperformance of the drug comes after prior CagriSema setbacks, posing a challenge to the market standing of its existing Wegovy (injection).
